# What This Desk Is, and What It Refuses To Be > About This Desk — Metabolic & Weight Research Peptides — How this briefing on Metabolic & Weight Research research peptides is assembled: what counts as evidence, how anecdote is labelled, why no dosing appears, and what the site refuses to publish. **EDITORIAL** An independent literature briefing on four metabolic peptides. No products, no protocols, no prescriptions — and every number traceable to a numbered source. ## What this is peptidemedsolutions is an independent research digest covering four peptides studied for weight and metabolic disease: semaglutide, tirzepatide, retatrutide and tesamorelin. It is organised the way a clinician's briefing note is organised, because that structure survives contact with a complicated evidence base better than a narrative does. Every compound page runs the same five beats in the same order: 1. **What it is** — structure, class, regulatory position. 2. **How it works** — mechanism, stated at the receptor rather than in metaphor. 3. **What the trials show** — design, population, duration, result, cited. 4. **What to watch** — reported effects and cited cautions, kept strictly apart. 5. **What remains unknown** — the questions no completed study has answered. That fifth section is the one most sites in this category omit, and it is the one that does the most work. A drug's unresolved list is usually more informative than its results section, particularly for a compound whose outcome trials have not reported. ## How the evidence is graded Three kinds of statement appear on this site, and conflating them is the characteristic failure of writing about this class. **Trial data** is the top tier. Every percentage, hazard ratio, participant count and duration on this site traces to a numbered entry on the [references list](/references). The rule applied while writing is narrow and strict: if a figure cannot be attributed to a source on that list, the figure is not printed and the finding is described qualitatively instead. That constraint has removed a number of specific-sounding percentages that a less disciplined page would have carried. It is a deliberate trade of precision for verifiability. **Regulatory labelling** is a different kind of claim. Boxed warnings, contraindications and approved indications are statements a regulator has made, not conclusions a trial reached. The thyroid C-cell warning on the incretin class is the clearest case: it derives from rodent studies at supratherapeutic exposures, and a dedicated safety review concluded that human thyroid- and pancreatic-cancer signals remain ones on which definitive conclusions cannot yet be drawn given the low event counts [5]. Both facts are true at once, and this site prints both. **Community reports** are the bottom tier and are always labelled as **anecdotal, not clinical evidence**. They come from patient-review aggregators, published exit-interview accounts and research-use forums. They are uncontrolled, self-selected, unverified and unauditable. They appear because they are frequently the only honest account of what a side effect feels like week by week — and because a reader who cannot find that here will find it somewhere that does not label it. No dose is ever attached to any of it. Where the underlying record carries no community material for a compound, as with [tesamorelin](/tesamorelin), none is manufactured. The absence is stated instead. ## Why there is no dosing here This site publishes no dosing schedules, no titration plans, no reconstitution or handling procedures, and no sourcing information. That is a fixed editorial position rather than a caution added at the end. Where a dose appears in the text it is the label of a study arm — the amount participants received under supervision in a specific cited trial — and it is written that way deliberately. "Participants in the 12 mg arm" is a description of a trial. It is not a suggestion, and the distance between those two things is the entire point. The reasoning is straightforward. Dose selection in this class depends on indication, comorbidity, concomitant medication, renal and hepatic function, tolerance during escalation and the response actually observed. A licensed clinician can assess those, order the relevant labs, adjust in response, and carry responsibility for what happens. A literature summary can do none of that, and one that pretended otherwise would be doing harm to exactly the readers most likely to act on it. The same reasoning governs the refusal to publish handling procedures for investigational material. A procedure implies the substance is characterised; for gray-market peptides, it is not. ## What this desk is not It is not a clinic, not a pharmacy, and not a vendor. Nothing on it is for sale, and it links to no seller. It is not medical advice. It does not diagnose, does not recommend, and does not tell any reader what to take or whether to take anything. It is not a promotional channel. Where the strongest evidence in a section is manufacturer-funded — as most phase 3 incretin data is — that is stated in the text rather than omitted. Where a headline number rests on phase 2 data against placebo rather than phase 3 data against an active comparator, the [comparison page](/compare) says so explicitly, because cross-trial comparison is the most common analytical error made about these compounds. It is also not neutral about accuracy. A figure that cannot be sourced does not appear, a mechanism that is inferred is marked as inferred, and an open question is left open. ## Corrections Errors of fact, attribution or citation are worth reporting and will be fixed. So are figures that have gone stale — this is a field where a phase 3 readout can invalidate a paragraph overnight, and retatrutide's outcome trials in particular will do exactly that when they report. The [contact page](/contact) has the editorial mailbox. Correspondence identifying a specific claim and the source that contradicts it is the most useful kind and gets handled first. --- A clinical-literature briefing on metabolic peptides: it reports what the trials measured and names what they left unresolved, and it neither practises medicine nor sells anything.